Reaction
Therapeutic Product Cross-Reactivity reporting signals
As of the last recalculation, Therapeutic Product Cross-Reactivity appears in 893 FAERS reports alongside 30 co-occurring drug terms. The strongest observed disproportionality signal is AMPICILLIN (PRR 184.2).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Ampicillin | 61 | 184.2 | 185.5 |
| Ampicillin Sodium | 61 | 184.2 | 185.5 |
| Cefuroxime | 29 | 61.1 | 61.2 |
| Amoxicillin | 152 | 55.7 | 55.8 |
| Moxifloxacin | 24 | 40.8 | 40.8 |
| Captopril | 12 | 29.5 | 29.5 |
| Moxifloxacin Hydrochloride | 24 | 28.3 | 28.4 |
| Phenytoin | 22 | 25.2 | 25.2 |
| Ceftriaxone Sodium | 38 | 24.1 | 24.1 |
| Phenobarbital | 14 | 22.9 | 22.9 |
| Carbamazepine | 57 | 21.1 | 21.1 |
| Ceftriaxone | 28 | 20.5 | 20.5 |
| Levofloxacin | 48 | 19.5 | 19.6 |
| Levofloxacin In 5% Dextrose | 48 | 19.5 | 19.6 |
| Daspone | 8 | 19.3 | 19.3 |
| Triamcinolone Acetonide Ointment Usp, 0.05% | 19 | 19.3 | 19.3 |
| Dapsone Gel, 5% | 8 | 19.3 | 19.3 |
| Piperacillin And Tazobactam | 10 | 18.4 | 18.4 |
| Dapsone | 8 | 17.6 | 17.6 |
| Lamotirigine | 51 | 17.5 | 17.5 |
| Lamotrigine Extended-Release | 51 | 17.5 | 17.5 |
| Lamotrigine Chewable Dispersible | 51 | 17.5 | 17.5 |
| Levodopa | 9 | 17.5 | 17.5 |
| Valproic Acid | 21 | 15.9 | 15.9 |
| Meropenem | 20 | 14.8 | 14.8 |
| Oxcarbazepine | 20 | 14.6 | 14.7 |
| Triamcinolone Acetonide | 19 | 14.6 | 14.6 |
| Rocuronium Bromide | 7 | 13.9 | 14.0 |
| Rifampicin | 6 | 13.9 | 13.9 |
| Pyrazinamide | 5 | 12.5 | 12.5 |